- Home
- VRAX vs CISS Comparison
VRAX vs CISS Comparison
Compare VRAX & CISS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRAX | CISS |
|---|---|---|
| Founded | 2013 | 2022 |
| Country | United Kingdom | Greece |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 1.6M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | VRAX | CISS |
|---|---|---|
| Price | $0.15 | $0.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 19.4M | 141.4K |
| Earning Date | 06-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $217,274.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.82 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $0.08 |
| 52 Week High | $1.18 | $5.93 |
Technical Indicators
Market Signals| Indicator | VRAX | CISS |
|---|---|---|
| Relative Strength Index (RSI) | 48.63 | 19.72 |
| Support Level | $0.10 | $0.20 |
| Resistance Level | $0.25 | $0.88 |
| Average True Range (ATR) | 0.03 | 0.07 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 49.32 | 3.15 |
Price Performance
Historical ComparisonAbout VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of its fleet is approximately 64,000 dwt.